What is Comparative Biosciences?
Comparative Biosciences, Inc. (CBI) operates as a specialized contract research organization (CRO) providing essential preclinical toxicology and pharmacokinetics services. The firm serves as a vital partner for biomedical and biopharmaceutical entities, facilitating efficacy studies across diverse therapeutic domains including oncology, dermatology, ophthalmology, and cardiovascular health. With rigorous accreditation from AAALAC and active registration with the FDA and USDA, CBI maintains a robust framework for research integrity. Their service model is designed to shepherd drug discovery programs from the initial target identification phase through to the complexities of clinical trial management, effectively bridging the gap between laboratory research and human therapeutic application.
How much funding has Comparative Biosciences raised?
Comparative Biosciences has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Comparative Biosciences
PPP
Public-Private Partnership
What's next for Comparative Biosciences?
With this late-stage capital, Comparative Biosciences is poised to scale its operational infrastructure to meet the increasing demand for high-fidelity preclinical data. The strategic focus will likely shift toward enhancing technological integration within their research facilities and expanding their capacity for complex, multi-therapeutic efficacy trials. As regulatory requirements for drug development continue to tighten globally, CBI's commitment to maintaining stringent compliance standards provides a competitive moat. Future growth will likely be driven by deepening partnerships with emerging biotech firms that require specialized, regulatory-ready data to advance their pipelines toward clinical milestones, thereby cementing the company's status as an indispensable link in the global drug development value chain.
See full Comparative Biosciences company page
